Indigo Pharmaceuticals, Inc. Signs License Agreement for INDI-702, a Drug for the Treatment of Arteriosclerosis Obliterans, With Nissan Chemical Industries, Ltd. and Taisho Pharmaceutical

Published: Jun 01, 2007

NEW YORK, June 1, 2007 (PRIME NEWSWIRE) -- Manhattan-based Indigo Pharmaceuticals, Inc. (Indigo), is a pharmaceutical company focused on the development of new treatments for cardiovascular diseases, currently concentrating on peripheral arterial disease, announced today that it has signed a license agreement for INDI-702 (previously NM-702; current development code in Japan: NT-702) with Tokyo-based Nissan Chemical Industries, Ltd. (Nissan Chemical) and Taisho Pharmaceutical Co., Ltd. (Taisho). Nissan Chemical and Taisho have been jointly developing INDI-702, a drug for the treatment of arteriosclerosis obliterans.

Back to news